Brief: Vaccinex Says Pepinemab Was Well-Tolerated In Phase 2 SIGNAL Study
22/09/2020 13:02
Sept 22 (Reuters) - Vaccinex Inc VCNX.O :
* TOP-LINE RESULTS OF PHASE 2 SIGNAL STUDY IN HUNTINGTON’S
DISEASE
SUPPORT POTENTIAL FOR COGNITIVE BENEFIT OF PEPINEMAB
* VACCINEX INC - RESULTS SUPPORT CONTINUED DEVELOPMENT IN
ALZHEIMER'S DISEASE AND IN MID-STAGE HUNTINGTON'S DISEASE
PATIENTS WITH GREATER COGNITIVE DEFICITS
* VACCINEX INC - OVERALL STUDY DOES NOT MEET PRE-SPECIFIED
CO-PRIMARY ENDPOINTS
* VACCINEX INC - KEY COGNITIVE ENDPOINTS TRENDING TOWARDS
BUT DID
NOT REACH STATISTICAL SIGNIFICANCE IN EARLY MANIFEST POPULATION
* VACCINEX INC - PEPINEMAB WAS WELL-TOLERATED
* VACCINEX - EXPECTS TO BEGIN ENROLLING PATIENTS THIS
MONTH IN A
NEW ALZHEIMER'S DISEASE STUDY OF PEPINEMAB AT 15 CLINICAL SITES
IN UNITED STATES
Source text for Eikon: ID:nGNX20YXlz
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease